News
Press Releases
Ascentage Pharma Appoints Renowned Oncologist Dr. David Sidransky, MD, to its Board as an Independent Non-Executive Director
SUZHOU, China and ROCKVILLE, Md., Apr. 2, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its appointment of Dr. David Sidransky, MD., a renowned oncologist, to the company’s Board of Directors as an independent non-executive director, Read More ›
Ascentage Pharma Announces 2020 Annual Results and Reports Launch Readiness for Its Core Drug Candidate
SUZHOU, China and ROCKVILLE, Md., U.S., Mar. 31, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today released its annual results for full year 2020, during which the company continued its rapid growth, despite the enormous challenges posed Read More ›
Ascentage Pharma’s First Third-Generation BCR-ABL Inhibitor in China Olverembatinib (HQP1351) Recommended for Breakthrough Therapy Designation
SUZHOU, China and ROCKVILLE, MD., the United States, Mar. 24, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has recommended the novel candidate drug olverembatinib (HQP1351) of Guangzhou Read More ›
Ascentage Pharma to Present the Latest Results from Six Preclinical Studies at AACR Annual Meeting 2021
SUZHOU, China and ROCKVILLE, Md., Mar. 10, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the latest preclinical research results of the company’s five novel drug candidates have been selected for presentations at the American Read More ›
Ascentage Pharma Released Preclinical Results of MDM2-p53 Inhibitor APG-115 in an Oral Presentation at WCLC 2020, Demonstrating Therapeutic Potential in STK11-Mutant Non-Small Cell Lung Cancer
SUZHOU, China and ROCKVILLE, Md., Feb. 2, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, announced that the company recently released the results from a preclinical study of APG-115, a novel MDM2-p53 inhibitor being developed by Ascentage Pharma, Read More ›
Ascentage Pharma Announces the Fifth Orphan Drug Designation Granted to Bcl-2 Inhibitor APG-2575 by the US FDA, and the Tenth Obtained by the Company
SUZHOU, China and ROCKVILLE, Md., Jan. 28, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) to the company’s novel Bcl-2 inhibitor, Read More ›
Ascentage Pharma Announces its 9th Orphan Drug Designation from the US FDA in 2020, Setting a Record for Chinese Biopharmaceutical Companies
SUZHOU, China and ROCKVILLE, Md., Jan. 5, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) to the company’s novel Bcl-2 inhibitor, APG-2575, for the treatment of Read More ›
Ascentage Pharma Officially Included in Shenzhen-Hong Kong Stock Connect Program
SUZHOU, China and ROCKVILLE, Md., Dec. 28, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company was officially included into the Shenzhen-Hong Kong Stock Connect program (the “Hong Kong Stock Connect”). This was officially announced by the Shenzhen Stock Read More ›
Ascentage Pharma’s Licensee UNITY Biotechnology Announces Milestone Reached in Clinical Development of Treatments for Age-Related Disease, Leading to Milestone Payment
SUZHOU, China and ROCKVILLE, Md., Dec. 22, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its licensee, UNITY Biotechnology (“UNITY”, NASDAQ:UBX), has dosed the first patient in a Phase I clinical study of drug candidate UBX1325 in patients with diabetic Read More ›
Ascentage Pharma Announces Updates on the Clinical Development of APG-2575, including an ORR of 70% in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
SUZHOU, China, and ROCKVILLE, MD, Dec. 10, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced updates on the clinical development of the company’s novel Bcl-2 inhibitor APG-2575, further demonstrating the drug candidate’s therapeutic potential. APG-2575 is Read More ›